FindTrial
Sign In

To study Efficacy and safety of fractional CO2 laser with oral itraconazole SB versus oral itraconazole SB in treatment of onychomycosis among patients attending tertiary care hospital bhavnagar

Efficacy and safety of fractional CO2 laser with oral superbioavailable itraconazole versus oral superbioavaible itraconazole in treatment of onychomycosis among patients attending tertiary care hospital bhavnagar- a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/047953
Enrollment
326
Registered
2022-12-07
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Super bioavailable itraconazole Galaxy fractional CO2 laser: Oral super bioavailable itraconazole 100mg twice a day for 7 days pulse therapy for 2 months Galaxy fractional CO2 laser-

Sponsors

Khatri Dimple Nileshkumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients equal or more than 18 years of age, of either gender presenting with one or more finger nail onychomycosis.

Exclusion criteria

Exclusion criteria: Pregnant and lactating female Patients with other nail disorders due to psoriasis ,chronic eczema ,lichen planus ,bacterial infection , subungual hematoma. Patients who had used topical and systemic antifungal in the preceding 3 months. Patients with SGOT and SGPT more than the normal range. Patients with history of cardiac disease.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of fractional co2 laser with oral itraconazole SB in treatment of onychomycosis using Onychomycosis severity index Timepoint: at baseline, 4 weeks, 8 weeks and 12 weeks—

Secondary

MeasureTime frame
To assess the side effects of fractional CO2 laser and oral Itraconazole SB in treatment of onychomycosis Timepoint: At baseline, 4 weeks , 8 weeks and 12 weeks.—

Countries

India

Contacts

Public ContactKhatri Dimple Nileshkumar

Government Medical College, Bhavnagar

hitamehta88@gmail.com9429503188

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026